Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ADAM9_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ADAM9_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ADAM9_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ADAM9_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ADAM9_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ADAM9_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ADAM9_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ADAM9_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ADAM9_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009013023 | Oral cavity | NEOLP | tissue migration | 78/2005 | 365/18723 | 1.61e-09 | 1.06e-07 | 78 |
GO:009013223 | Oral cavity | NEOLP | epithelium migration | 77/2005 | 360/18723 | 1.96e-09 | 1.24e-07 | 77 |
GO:004578532 | Oral cavity | NEOLP | positive regulation of cell adhesion | 88/2005 | 437/18723 | 3.28e-09 | 1.95e-07 | 88 |
GO:004254232 | Oral cavity | NEOLP | response to hydrogen peroxide | 41/2005 | 146/18723 | 4.37e-09 | 2.50e-07 | 41 |
GO:007155924 | Oral cavity | NEOLP | response to transforming growth factor beta | 59/2005 | 256/18723 | 8.84e-09 | 4.49e-07 | 59 |
GO:007156024 | Oral cavity | NEOLP | cellular response to transforming growth factor beta stimulus | 58/2005 | 250/18723 | 9.13e-09 | 4.56e-07 | 58 |
GO:000717923 | Oral cavity | NEOLP | transforming growth factor beta receptor signaling pathway | 48/2005 | 198/18723 | 4.01e-08 | 1.66e-06 | 48 |
GO:003461231 | Oral cavity | NEOLP | response to tumor necrosis factor | 55/2005 | 253/18723 | 2.23e-07 | 7.28e-06 | 55 |
GO:000717822 | Oral cavity | NEOLP | transmembrane receptor protein serine/threonine kinase signaling pathway | 70/2005 | 355/18723 | 3.04e-07 | 9.62e-06 | 70 |
GO:000722931 | Oral cavity | NEOLP | integrin-mediated signaling pathway | 29/2005 | 107/18723 | 1.72e-06 | 4.19e-05 | 29 |
GO:003249631 | Oral cavity | NEOLP | response to lipopolysaccharide | 65/2005 | 343/18723 | 3.30e-06 | 7.40e-05 | 65 |
GO:004854532 | Oral cavity | NEOLP | response to steroid hormone | 64/2005 | 339/18723 | 4.45e-06 | 9.55e-05 | 64 |
GO:190495133 | Oral cavity | NEOLP | positive regulation of establishment of protein localization | 61/2005 | 319/18723 | 4.85e-06 | 1.03e-04 | 61 |
GO:000223731 | Oral cavity | NEOLP | response to molecule of bacterial origin | 67/2005 | 363/18723 | 5.94e-06 | 1.20e-04 | 67 |
GO:001063223 | Oral cavity | NEOLP | regulation of epithelial cell migration | 56/2005 | 292/18723 | 1.07e-05 | 1.98e-04 | 56 |
GO:005122233 | Oral cavity | NEOLP | positive regulation of protein transport | 57/2005 | 303/18723 | 1.62e-05 | 2.79e-04 | 57 |
GO:003021631 | Oral cavity | NEOLP | keratinocyte differentiation | 32/2005 | 139/18723 | 2.16e-05 | 3.57e-04 | 32 |
GO:000650921 | Oral cavity | NEOLP | membrane protein ectodomain proteolysis | 15/2005 | 43/18723 | 2.17e-05 | 3.57e-04 | 15 |
GO:001003833 | Oral cavity | NEOLP | response to metal ion | 66/2005 | 373/18723 | 2.83e-05 | 4.34e-04 | 66 |
GO:00346161 | Oral cavity | NEOLP | response to laminar fluid shear stress | 8/2005 | 14/18723 | 2.83e-05 | 4.34e-04 | 8 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADAM9 | SNV | Missense_Mutation | | c.1158N>A | p.Ser386Arg | p.S386R | Q13443 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ADAM9 | SNV | Missense_Mutation | novel | c.1933N>C | p.Asp645His | p.D645H | Q13443 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-E2-A9RU-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |
ADAM9 | SNV | Missense_Mutation | novel | c.1439N>T | p.Cys480Phe | p.C480F | Q13443 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1PC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ADAM9 | deletion | Frame_Shift_Del | novel | c.1942delN | p.Lys649SerfsTer43 | p.K649Sfs*43 | Q13443 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ADAM9 | deletion | Frame_Shift_Del | novel | c.2429delC | p.Pro810LeufsTer26 | p.P810Lfs*26 | Q13443 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
ADAM9 | SNV | Missense_Mutation | novel | c.1825N>C | p.Ser609Pro | p.S609P | Q13443 | protein_coding | deleterious(0.01) | benign(0.405) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ADAM9 | SNV | Missense_Mutation | | c.2264N>T | p.Arg755Leu | p.R755L | Q13443 | protein_coding | tolerated(0.15) | benign(0.018) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ADAM9 | SNV | Missense_Mutation | | c.1028C>T | p.Ser343Phe | p.S343F | Q13443 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-EX-A1H6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ADAM9 | SNV | Missense_Mutation | | c.475N>C | p.Glu159Gln | p.E159Q | Q13443 | protein_coding | tolerated(0.26) | possibly_damaging(0.629) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ADAM9 | SNV | Missense_Mutation | | c.605N>C | p.Arg202Pro | p.R202P | Q13443 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |